Search Results
10
Everything
Search Filters
Organization
AiViva Biopharma
AiViva Biopharma Receives FDA Clearance to Administer AIV001 in Facial Skin by Intradermal Injection for Nonmelanoma Skin Cancer
December 09, 2024 07:03 ET
|
AiViva Biopharma
AIV001 is currently in development for evaluation in Superficial and Nodular Superficial Basal Cell Carcinoma (sBCC and nBCC) COSA MESA, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma...
AiViva Biopharma Completes Enrollment in a Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
August 23, 2024 07:00 ET
|
AiViva Biopharma
Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has fully...
AiViva Biopharma Completes Phase 1/2 Clinical Trial of AIV001 Administration in Patients with Nonmelanoma Skin Cancer
December 11, 2023 08:00 ET
|
AiViva Biopharma
Novel Non-surgical Intradermal Treatment for Basel Cell Carcinoma COSA MESA, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced...
AiViva Biopharma Appoints Lester J. Kaplan, PhD to the Board of Directors
September 18, 2023 06:00 ET
|
AiViva Biopharma
COSTA MESA, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today...
AiViva Biopharma 任命 Jung-Chin (Rongjin) Lin 為董事會成員
August 29, 2023 19:00 ET
|
AiViva Biopharma
加利福尼亞州科斯塔梅薩, Aug. 29, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc. 是一家臨床階段生物技術公司，致力於開發創新療法以應對潛力巨大的醫療需求，其於今日宣布任命 Jung-Chin (Rongjin) Lin 先生為其董事會成員。Jung-Chin (Rongjin) Lin 先生是 Center Laboratories,...
AiViva Biopharma Appoints Jung-Chin (Rongjin) Lin, to the Board of Directors
August 29, 2023 19:00 ET
|
AiViva Biopharma
COSTA MESA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company developing innovative therapies to address major unmet medical needs, today...
AiViva Biopharma Initiates Phase 1 Clinical Trial of AIV007 for Age-Related Macular Degeneration and Diabetic Macular Edema
May 22, 2023 06:00 ET
|
AiViva Biopharma
Novel JEL™ Technology for Periocular Administration COSTA MESA, Calif., May 22, 2023 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a...
AiViva Biopharma Initiates Phase 1/2 Clinical Trial of AIV001 for Nonmelanoma Skin Cancer
October 02, 2020 08:00 ET
|
AiViva Biopharma
NEWPORT BEACH, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun dosing patients diagnosed with superficial or...
AiViva Biopharma Announces Positive Data from Phase 1/2a Clinical Trial of AIV001 for Dermal Scarring and Wound Healing
June 25, 2020 08:00 ET
|
AiViva Biopharma
AIV001 was shown to be safe and well tolerated after local intradermal treatment of incisional wounds Reduction in fibrosis was observed from single AIV001 treatment post-wounding NEWPORT BEACH,...